At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 8, 2026 at 17:00 ET
Dianthus Therapeutics announced a conference call to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP, scheduled for March 9, 2026. The event is material as it pertains to a key clinical milestone for a Phase 3 program in a severe autoimmune disease, but no results have been disclosed yet.
- Company to discuss interim responder analysis from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.
- Data discussion scheduled for March 9, 2026, at 8:00 a.m. ET via webcast and conference call.
- No clinical results are released in this announcement, only logistical details for an upcoming event.
- Claseprubart is being evaluated for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare and severe autoimmune neurological disorder.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access